{2-[1-(4-Bromo-3-methyl-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethoxy]-ethyl}-trimethyl-silane | 524773-77-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {2-[1-(4-Bromo-3-methyl-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethoxy]-ethyl}-trimethyl-silane
• CAS: 524773-77-1
• 化学式: C₁₆H₂₁BrF₆O₂Si
• 分子量: 467.321
• InChiKey: ODCWGQSLNNHEOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.41
• 重原子数：
  26.0
• 可旋转键数：
  7.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  {2-[1-(4-Bromo-3-methyl-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethoxy]-ethyl}-trimethyl-silane 在 吡啶 、 六甲基磷酰三胺 、 lithium hydroxide 、 氯化亚砜 、 四丁基氟化铵 、 双(三甲基硅烷基)氨基钾 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 16.5h， 生成 2-{4-[1-(3,4-Bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-3-methyl-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol
  参考文献：
  名称：

  Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

  摘要：

  A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00615-7
• 作为产物：
  描述：

  2,5-二溴甲苯 在 正丁基锂 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 20.5h， 生成 {2-[1-(4-Bromo-3-methyl-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethoxy]-ethyl}-trimethyl-silane
  参考文献：
  名称：

  Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters

  摘要：

  A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor that is well absorbed and that presents a shorter half-life than L-791,943 in a variety of animal species. The efficacy of L-826,141 is also demonstrated in different in vivo models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00615-7